|Bid||181.40 x 1400|
|Ask||211.12 x 1800|
|Day's range||185.15 - 191.04|
|52-week range||119.95 - 192.00|
|Beta (5Y monthly)||1.06|
|PE ratio (TTM)||18.99|
|Earnings date||31 Jan 2022 - 04 Feb 2022|
|Forward dividend & yield||0.28 (0.15%)|
|Ex-dividend date||20 Jan 2022|
|1y target est||188.82|
WALTHAM, Mass., December 08, 2021--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced the research use only (RUO) launch of the NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 to accelerate the detection of SARS-CoV-2 variants. This complete next generation sequencing (NGS) solution will allow laboratories to increase sequencing throughput and make reliable variant identifications.
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
WALTHAM, Mass., November 29, 2021--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the performance of its SARS-CoV-2 RT-PCR assays are not impacted by the emergence of Omicron (B.1.1.529), a variant of concern that was recently identified by the World Health Organization (WHO).